Last updated 16 days ago
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
496 patients around the world
Available in Chile, Argentina, United States
Sanofi
1Research sites
496Patients around the world
This study is for people with
Dermatitis
Atopic dermatitis
Requirements for the patient
From 12 Years
All Gender
Medical requirements
StudySHORE
SponsorSanofi
Conditions
Atopic dermatitis
Requirements
From 12 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06224348
